Equities research analysts at Scotiabank began coverage on shares of Aphria (OTCMKTS:APHQF) in a research report issued on Wednesday. The brokerage set a “buy” rating on the stock.

Separately, Cann started coverage on shares of Aphria in a research report on Friday, October 12th. They set a “sell” rating and a $19.00 price target on the stock.

OTCMKTS:APHQF opened at $14.89 on Wednesday. Aphria has a 1-year low of $5.07 and a 1-year high of $19.87.

Aphria (OTCMKTS:APHQF) last released its quarterly earnings data on Wednesday, August 1st. The company reported ($0.03) earnings per share for the quarter. The firm had revenue of $9.32 million for the quarter.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

See Also: What is a Stop Order?

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.